Literature DB >> 6670

Gastrointestinal absorption of carbenoxolone in the rat determined in vitro and in situ: deviations from the pH-partition hypothesis.

J W Bridges, J B Houston, M J Humphrey, W E Lindup, D V Parke, J S Shillingford, D G Upshall.   

Abstract

The absorption of [14C] carbenoxolone from everted rat ileum in vitro and from rat stomach and ileum in situ has been examined. The rate of its mucosal to serosal transfer in vitro increases as pH increases from 5 to 8 whereas the amount bound to ileum tissue decreases with increased pH; absorption closely parallels the drug's solubility. The uptake of carbenoxolone in situ is bi-exponential and the rate constants for the two processes, have been calculated. Absorption in situ, and biliary excretion, of the drug increases with increasing pH from 5.0 to 7.4. Tissue binding to the ileum in situ is not dependent on pH except below pH 5.0 when extensive tissue accumulation of carbenoxolone occurs because of its low solubility. Tissue binding to the stomach increases markedly with decrease of pH from 7.4 to 6.5 and at pH 6.5 is 80 times greater than binding to the intestine. The rate of absorption from the stomach, at pH 6.5-7.4, was much less than that from the intestine in situ. When allowance is made for the binding of carbenoxolone to the stomach, contrary to the pH-partition hypothesis, correlation is apparent between its absorption and the amount present in the ionized form.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6670     DOI: 10.1111/j.2042-7158.1976.tb04109.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  The effect of E. coli STa enterotoxin on the absorption of weakly dissociable drugs from rat proximal jejunum in vivo.

Authors:  G T McEwan; M L Lucas
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

2.  Blood flow in intestinal absorption models.

Authors:  D Winne
Journal:  J Pharmacokinet Biopharm       Date:  1978-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.